Glaukos Appoints Denice Torres and Dr Leana Wen to its Board of Directors pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2020. Preliminary and unaudited total net sales for the fourth quarter of 2020 are expected to be approximately $73 million, consisting of approximately $58 million in Glaucoma net sales and approximately $15 million in Corneal Health net sales. Preliminary and unaudited total net sales for the full year of 2020 are expected to be approximately $225 million, consisting of approximately $179 million in Glaucoma net sales and approximately $46 million in Corneal Health net sales.
Press release content from Business Wire. The AP news staff was not involved in its creation.
U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP
January 13, 2021 GMT
SAN CLEMENTE, Calif. (BUSINESS WIRE) Jan 13, 2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its
iStent infinite ™
Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy.